Skip to content
Medical Health Aged Care

High blood pressure and shorter sleep may worsen brain decline: study

Monash University 2 mins read

People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.

 

Published in the Journal of the American Heart Association, researchers assessed whether the combined effect of hypertension and short sleep duration had a negative impact on brain health.

 

They used data from 682 dementia-free Framingham Heart Study participants who completed overnight sleep recordings, self-reported sleep duration questionnaires, blood pressure and cognitive assessments; 637 underwent brain magnetic resonance imaging (MRI).

 

In those with high blood pressure, shorter sleep duration was associated with poorer executive functioning and markers of brain injury and accelerated brain ageing on MRI. These associations were not observed in people with normal blood pressure.

 

These results were similar following adjustment for genetic, clinical and demographic variables.

 

Insufficient sleep is generally defined as less than seven hours. Participants reported sleeping an average of seven hours per night, with 32 percent reporting a short sleep duration of less than six hours per night.

Moderate to severe obstructive sleep apnoea was identified in 16 per cent of individuals, and almost one‐quarter of the overall sample reported using sleeping pills regularly.

 

“In individuals with hypertension, shorter sleep duration was associated with worse cognitive performance and greater brain injury,” the study found.


“Inadequate sleep has been linked to hypertension and dementia, and though the underlying mechanisms remain unclear, it is possible that short sleep and hypertension interact to increase the risk of cognitive impairment and vascular brain injury.”

 

While the cohort was based in the US, researchers believe the results would be similar in Australia.

 

Senior author Associate Professor Matthew Pase, from the Monash University School of Psychological Sciences and Turner Institute for Brain and Mental Health, said short sleep duration was already associated with an increased risk of cognitive impairment and dementia.

 

He said while short sleep was associated with elevated blood pressure, the combination of short sleep and hypertension on brain health was unclear before this study.

 

“These findings have significance, given that over one-third of Australians experience sleep problems,” Associate Professor Pase said. “Importantly, sleep problems and hypertension are treatable. Addressing these factors may offer new opportunities for intervention to improve brain health.”

 

First author Dr Stephanie Yiallourou, from the Monash University School of Psychological Sciences and Turner Institute for Brain and Mental Health, said screening people with high blood pressure for insufficient sleep could allow tailored therapies to improve brain aging and reduce brain injury.

 

Dr Yiallourou said they could also be targeted for new randomised controlled trials to determine the efficacy of sleep treatments and blood pressure–lowering therapies in preventing or delaying cognitive impairment.

 

“The next step in this research is to explore whether the double hit of short sleep and hypertension is associated with dementia risk in the long-term,” she said.

 

This work was supported by an Alzheimer’s Association Grant.

 

For media enquiries please contact:

 

Monash University

Cheryl Critchley – Media and Communications Manager (medical)
E:
[email protected]

T: +61 (0) 477 571 442

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: 
[email protected]
T: +61 (0) 3 9903 4840

 

***ENDS***

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.